Swedish Orphan Biovitrum Stock Current Valuation
| BIOVF Stock | USD 25.76 2.89 12.64% |
Valuation analysis of Swedish Orphan Biovitrum helps investors to measure Swedish Orphan's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Swedish Orphan's price fluctuation is not too volatile at this time. Calculation of the real value of Swedish Orphan Biovitrum is based on 3 months time horizon. Increasing Swedish Orphan's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Swedish Orphan Biovitrum is useful when determining the fair value of the Swedish pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Swedish Orphan. Since Swedish Orphan is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Swedish Pink Sheet. However, Swedish Orphan's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.76 | Real 22.74 | Hype 25.76 | Naive 25.55 |
The real value of Swedish Pink Sheet, also known as its intrinsic value, is the underlying worth of Swedish Orphan Biovitrum Company, which is reflected in its stock price. It is based on Swedish Orphan's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Swedish Orphan's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Swedish Orphan's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Swedish Orphan Biovitrum helps investors to forecast how Swedish pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Swedish Orphan more accurately as focusing exclusively on Swedish Orphan's fundamentals will not take into account other important factors: Swedish Orphan Biovitrum Company Current Valuation Analysis
Swedish Orphan's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Swedish Orphan Current Valuation | 7.05 B |
Most of Swedish Orphan's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Swedish Orphan Biovitrum has a Current Valuation of 7.05 B. This is 50.94% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 57.61% higher than that of the company.
Swedish Orphan Biovitrum is the top company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 7.05 Billion. Swedish Orphan totals roughly 7.05 Billion in current valuation claiming about 100% of equities under Drug Manufacturers—Specialty & Generic industry.Swedish Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 7.05 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 70.55 % | |||
| Price To Earning | 20.33 X | |||
| Price To Book | 2.58 X | |||
| Price To Sales | 3.68 X | |||
| Revenue | 15.53 B | |||
| Gross Profit | 14.38 B | |||
| EBITDA | 5.72 B | |||
| Net Income | 2.68 B | |||
| Cash And Equivalents | 280.15 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 8.78 B | |||
| Debt To Equity | 0.41 % | |||
| Current Ratio | 1.02 X | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | 5.47 B | |||
| Earnings Per Share | 0.98 X | |||
| Price To Earnings To Growth | 34.30 X | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.39 | |||
| Market Capitalization | 6.99 B | |||
| Total Asset | 48.66 B | |||
| Working Capital | 1.16 B | |||
| Current Asset | 2.65 B | |||
| Current Liabilities | 1.49 B | |||
| Net Asset | 48.66 B |
About Swedish Orphan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Swedish Orphan Biovitrum's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Swedish Orphan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Swedish Orphan Biovitrum based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Swedish Orphan
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Swedish Orphan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Swedish Orphan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Swedish Orphan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Swedish Orphan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Swedish Orphan Biovitrum to buy it.
The correlation of Swedish Orphan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Swedish Orphan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Swedish Orphan Biovitrum moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Swedish Orphan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Swedish Orphan Biovitrum. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Swedish Pink Sheet analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |